Nonalcoholic fatty liver disease (NAFLD) consists of the entire spectrum of fatty liver disease
in patients without significant alcohol consumption, ranging from nonalcoholic fatty liver …

Hepatitis B virus (HBV) cannot be eliminated completely from infected hepatocytes because
of the presence of intrahepatic covalently closed circular DNA (cccDNA). As chronic hepatitis …

Assessing liver fibrosis is important for predicting the efficacy of antiviral therapy and patient
prognosis. Liver biopsy is the gold standard for diagnosing liver fibrosis, despite its …

Aims No pharmacological therapies are approved for non‐alcoholic fatty liver disease
(NAFLD). Luseogliflozin, a sodium glucose cotransporter 2 inhibitor, has been developed for …

Background: Low skeletal muscle mass is significantly associated with severe adverse
events (AEs) from chemotherapy, and low tolerability leads to decreased survival. We aimed …

OBJECTIVES: Noninvasive markers of liver fibrosis in patients with primary biliary cirrhosis
(PBC) are needed for predicting disease progression. As theWisteria floribundaagglutinin …

Non-alcoholic fatty liver disease (NAFLD) is a challenging disease caused by multiple
factors, which may partly explain why it still remains an orphan of adequate therapies. This …

Background Nonalcoholic fatty liver disease (NAFLD) is common in the general population
but identifying patients with high-risk nonalcoholic steatohepatitis (NASH) who are …

Abstract Background and Aim Hepatic stellate cells (HSCs) play a central role in hepatic
fibrosis and are regulated by Kupffer cells (KCs). Wisteria floribunda agglutinin‐positive Mac …

Liver fibrosis is a common pathway in most chronic liver diseases, characterized by
excessive extracellular matrix accumulation. Without treatment, fibrosis will ultimately result …